A 26-year-old woman with differentiated papillary thyroid carcinoma received 192 mCi of radioiodine 131 (I-131) under recombinant thyroidstimulating hormone (TSH) treatment for persistent upper mediastinal metastasis. Radioiodine whole-body scintigraphy (WBS) was performed nine days later and showed targeting of the I-131 at the mediastinal metastasis, but also demonstrated an additional focus of significantly increased uptake near the scalp (see Figure 1) . Repositioning of her coiffure by the nuclear medicine technologist revealed the source of uptake to be the hair; there was also slightly increased uptake at the fingertips. Further history was later obtained from the patient and revealed a hair-sucking habit.
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Discussion
Cutaneous metastases are a rare manifestation of differentiated thyroid carcinomas 1 and typically signify advanced disease with poor prognosis. [2] [3] [4] When present, the scalp is the most common site of cutaneous thyroid cancer metastases. 2, [4] [5] [6] [7] Such lesions are usually evident on physical exam as erythematous, purple, or non-pigmented plaques or nodules, [2] [3] [4] [5] 7 but can also mimic other dermatologic conditions such as topical infections, benign cysts, alopecia, or other cutaneous malignant neoplasms. Physiologic I-131 uptake can be visualized in:
• tissues that concentrate iodine, e.g., tissues expressing the sodiumiodide symporter which include the thyroid (or ectopic thyroid tissue), salivary and mammary glands, bowel, lung, and nasal mucosa;
• tissues where thyroid hormones and thyroglobulin are degraded, i.e., the liver; or
• in radioiodine excretory products including urine, feces, saliva, and sweat. 10, 11 Also, there can be increased I-131 uptake at sites of unrelated pathologic processes, including:
• inflammation or trauma, as a result of increased blood flow and capillary permeability; or • other benign or malignant tumors, typically due to functional sodium-iodide symporter expression.
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Abstract
Contamination of external sites with secretions or excretory products can mimic metastases and yield false positives in radioiodine whole-body scintigraphy for thyroid cancer. We present a case of a 26-year-old woman with differentiated papillary thyroid carcinoma who received radioiodine 131 (I-131) for treatment of persistent upper mediastinal metastasis. Her post-treatment whole-body scintigraphy revealed an unexpected focus of increased uptake near the scalp in addition to the mediastinal lesion. Although the scalp is the most common site of cutaneous thyroid cancer metastasis, differentiated thyroid cancers rarely manifest with cutaneous thyroid cancer metastasis and thus it is prudent to consider etiologies of false positive I-131 uptake in such cases. Contamination of our patient's hair from salivary secretions was confirmed on history and with coiffure repositioning during whole-body scintigraphy.
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